China Pharma (NYSE:CPHI) Stock Price Down 4.4% – Time to Sell?

China Pharma Holdings, Inc. (NYSE:CPHI) shares fell 4.4% during mid-day trading on Monday . The stock traded as low as $1.07 and last traded at $1.08. Approximately 393,419 shares were traded during trading, a decline of 80% from the average session volume of 1,922,649 shares. The stock had previously closed at $1.13.

China Pharma Stock Performance

The stock’s 50 day moving average price is $1.09 and its 200 day moving average price is $0.83. The company has a current ratio of 0.79, a quick ratio of 0.26 and a debt-to-equity ratio of 0.22. The firm has a market cap of $43.76 million, a PE ratio of -1.96 and a beta of 1.05.

Institutional Investors Weigh In On China Pharma

A hedge fund recently raised its stake in China Pharma stock. Citadel Advisors LLC boosted its stake in China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,426 shares of the company’s stock after acquiring an additional 7,356 shares during the quarter. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 at the end of the most recent reporting period.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.